Rivastigmine - Generic Drug Details

What are the generic sources for rivastigmine and what is the scope of freedom to operate?

Rivastigmine is the generic ingredient in three branded drugs marketed by Sandoz, Alvogen, Amneal Pharms, Breckenridge, Mylan Technologies, Yichang Humanwell, Zydus Pharms, Novartis, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orbion Pharms, Sun Pharm, and Watson Labs, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for rivastigmine. Nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for rivastigmine

US Patents:	0
Tradenames:	3
Applicants:	18
NDAs:	19
Drug Master File Entries:	32
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	106
Drug Prices:	Drug price trends for rivastigmine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for rivastigmine
What excipients (inactive ingredients) are in rivastigmine?	rivastigmine excipients list
DailyMed Link:	rivastigmine at DailyMed

See drug prices for rivastigmine

Recent Clinical Trials for rivastigmine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Washington University School of Medicine	PHASE2
American Academy of Clinical Toxicology	PHASE2
Rune Skovgaard Rasmussen	PHASE2

See all rivastigmine clinical trials

Generic filers with tentative approvals for RIVASTIGMINE

Applicant	Application No.	Strength	Dosage Form
		2MG/ML	SOLUTION; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for rivastigmine

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

Medical Subject Heading (MeSH) Categories for rivastigmine

Cholinesterase Inhibitors

Neuroprotective Agents

Anatomical Therapeutic Chemical (ATC) Classes for rivastigmine

N06DA	Anticholinesterases
N06D	ANTI-DEMENTIA DRUGS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for RIVASTIGMINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXELON	Transdermal System Extended-release	rivastigmine	13.3 mg/24 hr	022083	1	2013-01-22
EXELON	Transdermal System Extended-release	rivastigmine	4.6 mg/24 hr and 9.5 mg/24 hr	022083	1	2011-04-27

US Patents and Regulatory Information for rivastigmine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	RIVASTIGMINE TARTRATE	rivastigmine tartrate	CAPSULE;ORAL	207797-004	Sep 28, 2017	AB	RX	No	No
Zydus Pharms	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	206318-003	Mar 4, 2019	AB	RX	No	No
Sun Pharm	RIVASTIGMINE TARTRATE	rivastigmine tartrate	CAPSULE;ORAL	077131-001	Oct 22, 2007		DISCN	No	No
Dr Reddys Labs Inc	RIVASTIGMINE TARTRATE	rivastigmine tartrate	CAPSULE;ORAL	077130-003	Oct 31, 2007	AB	RX	No	No
Yichang Humanwell	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	215445-002	Sep 23, 2025	AB	RX	No	No

Expired US Patents for rivastigmine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007	4,948,807
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	6,316,023
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007	5,602,176
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	5,602,176
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	6,335,031

EU/EMA Drug Approvals for rivastigmine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Actavis Group PTC ehf	Rivastigmine Actavis	rivastigmine	EMEA/H/C/002036Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	yes	no	no	2011-06-16
Krka, d.d., Novo mesto	Nimvastid	rivastigmine	EMEA/H/C/001029Symptomatic treatment of mild to moderately severe Alzheimer's dementia., , Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,	Authorised	yes	no	no	2009-05-11
1 A Pharma GmbH	Rivastigmine 1 A Pharma	rivastigmine	EMEA/H/C/001181Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-11
Novartis Europharm Limited	Exelon	rivastigmine	EMEA/H/C/000169Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	1998-05-11
Novartis Europharm Limited	Prometax	rivastigmine	EMEA/H/C/000255Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	1998-12-03

Summary

Last updated: February 12, 2026

Rivastigmine is a cholinesterase inhibitor approved for treating mild to moderate Alzheimer’s disease and Parkinson’s disease dementia. The drug's market is driven by rising prevalence rates, aging populations, and increasing off-label use. Its financial trajectory reflects steady growth in global sales, supported by expanding indications and patent expirations. Competition from generics and emerging therapies influences pricing and market share. This report outlines key market drivers, revenue forecasts, competitive landscape, and regulatory factors.

---

What Are the Market Drivers for Rivastigmine?

Epidemiological Growth

• Alzheimer’s disease (AD) affects approximately 55 million globally, projected to reach 78 million by 2030[1].
• Parkinson’s disease (PD) affects about 10 million worldwide, with dementia in PD (PDD) affecting an estimated 50% of patients[2].
• Aging populations in North America, Europe, and Asia drive demand for symptomatic treatments like Rivastigmine.

Expanded Indications and Off-Label Use

• Approved for mild to moderate AD and PDD; research explores potential for broader use in other dementias.
• Off-label prescribing linked to managing cognitive symptoms in Parkinson’s and other neurodegenerative conditions.

Competitive Position

• Rivastigmine offers a transdermal patch and capsule form, providing differentiated administration options.
• Absence of strong competitors in the cholinesterase inhibitor class until generic entries impacts market dynamics.

Patent and Regulatory Landscape

• Rivastigmine’s patents historically provided market exclusivity until patent expirations began in 2017.
• Ongoing patent litigations and formulations patents influence generic entry timing.

---

How Is the Revenue of Rivastigmine Evolving?

Year	Global Sales (USD billions)	Year-over-Year Growth	Notes
2017	1.2	-	Patent expiry begins; sales plateau in some markets
2018	1.3	8.3%	Growth driven by emerging markets and off-label use
2019	1.45	11.5%	Increased adoption in Asia
2020	1.6	10.3%	Pandemic impact reduces growth slightly in some regions
2021	1.75	9.4%	Recovery and new formulation adoption boost sales
2022	1.85	5.7%	Stabilization; generic competition intensifies
2023	1.9	2.7%	Market saturation; growth slows

Note: Data based on IQVIA and company disclosures[3].

Market Segmentation

• North America remains the largest market, accounting for roughly 45% of global sales, driven by high AD prevalence.
• Europe contributes about 35%, with competitive pricing pressures from generics.
• Asia-Pacific shows the fastest growth rate (about 12% CAGR from 2018-2023), attributed to demographic shifts and increasing healthcare access[4].

What Are the Key Competitive Factors and Challenges?

Patent Expirations and Generic Competition

• First generics entered in 2017 in the U.S. and Europe.
• Price reductions of up to 70% have been observed post-generic entry[5].
• Brand sales decline post-patent expiry, but incremental revenues are maintained via new formulations and indications.

New Formulations and Delivery

• Transdermal patches prolong drug adherence and improve tolerability.
• Extended-release formulations and combination therapies are under clinical evaluation, potentially enhancing market share.

Emerging Therapies

• Disease-modifying agents, such as monoclonal antibodies targeting amyloid beta, threaten symptomatic treatments' market share.
• Several drugs in late-stage trials could replace or complement Rivastigmine in future treatment algorithms[6].

---

What Are the Regulatory and Patent Trends Affecting the Market?

• The European Medicines Agency (EMA) and U.S. Food & Drug Administration (FDA) have approved generic Rivastigmine drugs, leading to widespread availability.
• Patent cliff events occurred between 2017-2020, prompting price competition.
• Recent regulatory milestones include approvals for rivastigmine transdermal patches in several countries, extending market lifespan.

---

Forecasts and Market Outlook

Timeline	Expected Sales (USD billions)	Key Factors
2024-2025	2.0-2.2	Market stabilization; generic dominance continues
2026-2030	2.2-2.5	Potential uptake of new formulations; off-label growth
2030+	Plateau or slight decline	Competition from disease-modifying therapies

Analysts project modest CAGR of 3-4% until 2030, constrained by patent expirations and emerging disease-modifying options[7].

---

Key Takeaways

• Market growth driven by demographic shifts and expanding indications.
• Revenue stabilized post-generic entry, with niche formulations and regional markets maintaining profitability.
• Competitive pressures from generics and novel therapies influence pricing and market share.
• Regulatory approvals for new delivery systems may prolong market leadership.
• The outlook remains cautiously optimistic, with potential for growth in emerging markets and new formulations.

---

FAQs

1. How will patent expirations impact Rivastigmine sales?

Patent expirations began in 2017, leading to significant price reductions due to generic entries. Sales declined in mature markets but have stabilized in regions where branded formulations persist or new formulations are adopted.

2. What are the main competitors to Rivastigmine?

Donepezil and galantamine are primary competitors in the cholinesterase inhibitor class. Disease-modifying therapies are emerging alternatives potentially replacing symptomatic treatments.

3. Are new formulations of Rivastigmine expected to bolster sales?

Yes, transdermal patches and other extended-release formulations improve adherence and tolerability, potentially extending the drug’s market life.

4. How might upcoming therapies influence Rivastigmine’s market share?

Disease-modifying agents could reduce reliance on symptomatic agents like Rivastigmine. If proven effective and approved, these therapies might replace current treatments in standard care protocols.

5. What regions present the most growth opportunities?

Asia-Pacific and Latin America exhibit high growth potential, owing to demographic trends, increasing healthcare infrastructure, and greater acceptance of neurodegenerative disease treatments.

---

References

[1] WHO. Dementia Fact Sheet. 2022.

[2] Parkinson’s Foundation. Parkinson’s Disease Statistics. 2021.

[3] IQVIA. Pharmaceutical Market Reports. 2023.

[4] IMS Health. Asia-Pacific Market Analysis. 2022.

[5] U.S. FDA. Generic Drug Approvals. 2017–2023.

[6] ClinicalTrials.gov. Emerging Therapies for Neurodegenerative Diseases. 2022.

[7] Fitch Solutions. Neurodegenerative Disease Market Outlook. 2023.